| 10.54 -0.04 (-0.38%) | 10-14 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 14.36  |
1-year : | 15.74 |
| Resists | First : | 12.29 |
Second : | 13.47 |
| Pivot price | 11.15 |
|||
| Supports | First : | 10.38 | Second : | 8.64 |
| MAs | MA(5) : | 10.82 |
MA(20) : | 11.2 |
| MA(100) : | 12.38 |
MA(250) : | 10.94  |
|
| MACD | MACD : | -0.5 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 9.4 |
D(3) : | 10.4 |
| RSI | RSI(14): 36.9 |
|||
| 52-week | High : | 17.43 | Low : | 5.59 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CRMD ] has closed above bottom band by 6.6%. Bollinger Bands are 54.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 10.74 - 10.81 | 10.81 - 10.87 |
| Low: | 10.21 - 10.31 | 10.31 - 10.39 |
| Close: | 10.4 - 10.54 | 10.54 - 10.64 |
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Tue, 14 Oct 2025
CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip? - sharewise.com
Fri, 10 Oct 2025
CorMedix Inc. (CRMD) Stock Analysis: A Biotech Powerhouse With 86% Upside Potential - DirectorsTalk Interviews
Thu, 09 Oct 2025
CorMedix: Challenging Long-Term Risk-Reward, Maintain Sell - Seeking Alpha
Sun, 05 Oct 2025
CorMedix (CRMD): Assessing Valuation Following Phase III REZZAYO Trial Enrollment and Melinta Growth Moves - Sahm
Wed, 17 Sep 2025
Citizens JMP Reiterates a Buy Rating on CorMedix Inc. (CRMD) - Yahoo Finance
Thu, 04 Sep 2025
Institutional Confidence Rises as CorMedix Inc. (CRMD) Hits Profitability - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 78 (M) |
| Held by Insiders | 6.942e+007 (%) |
| Held by Institutions | 7.5 (%) |
| Shares Short | 11,890 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 4.985e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 42.1 % |
| Operating Margin | 49.1 % |
| Return on Assets (ttm) | 19.8 % |
| Return on Equity (ttm) | 38.3 % |
| Qtrly Rev. Growth | 4 % |
| Gross Profit (p.s.) | 448.32 |
| Sales Per Share | 6.56649e+007 |
| EBITDA (p.s.) | 6.27892e+007 |
| Qtrly Earnings Growth | 0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 30 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 6.58 |
| Dividend | 0 |
| Forward Dividend | 1.556e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|